{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:40:15Z","timestamp":1731044415616,"version":"3.28.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Equity Health"],"DOI":"10.1186\/s12939-024-02318-w","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:53:11Z","timestamp":1731041591000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision medicine and Friedreich ataxia: promoting equity, beneficence, and informed consent for novel gene therapies"],"prefix":"10.1186","volume":"23","author":[{"given":"Faith A. A.","family":"Kwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evie","family":"Kendal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"2318_CR1","volume-title":"Principles of Biomedical Ethics","author":"TL Beauchamp","year":"2019","unstructured":"Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 8th ed. Oxford: Oxford University Press; 2019.","edition":"8"},{"issue":"3","key":"2318_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/15265161.2014.880313","volume":"14","author":"BE Berkman","year":"2014","unstructured":"Berkman BE, Hull SC. The right not to know in the genomic era: time to break from tradition? Am J Bioeth. 2014;14(3):28\u201331.","journal-title":"Am J Bioeth"},{"key":"2318_CR3","unstructured":"Biogen. 2024. Biogen received European Commission approval for Skyclarys\u00ae (omaveloxolone), the first therapy to treat Friedreich\u2019s ataxia. Biogen media release, February 12, 2024. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-received-european-commission-approval-skyclarysr"},{"key":"2318_CR4","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","volume":"10","author":"W Chen","year":"2020","unstructured":"Chen W, Hu Y, Ju D. Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B. 2020;10:1347\u201359.","journal-title":"Acta Pharm Sin B"},{"key":"2318_CR5","doi-asserted-by":"crossref","unstructured":"Ciss\u00e9 CAK, Ciss\u00e9 L, Ba HO, Samass\u00e9kou O, Simaga A, Tam\u00e9ga A, Diarra S, Diallo SH, Coulibaly T, Diallo S, Yalcouy\u00e9 A, Maiga AB, Keita M, Fischbeck KH, Traor\u00e9 SF, Guinto CO, Landour\u00e9 G, from the H3Africa Consortium. 2021. Friedreich ataxia in a family from Mali, West Africa\/Friedreich ataxia in a Malian family. Clin Case Rep, 9(5), e04065.","DOI":"10.1002\/ccr3.4065"},{"key":"2318_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","volume":"124","author":"A Cook","year":"2017","unstructured":"Cook A, Giunti P. Friedreich\u2019s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124:19\u201330.","journal-title":"Br Med Bull"},{"key":"2318_CR7","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1073\/pnas.94.14.7452","volume":"94","author":"M Coss\u00e9e","year":"1997","unstructured":"Coss\u00e9e M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL, Koenig M. Evolution of the Friedreich\u2019s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A. 1997;94:7452\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2318_CR8","unstructured":"Drugs.com. 2024. Skyclarys prices, coupons and patient assistance programs. https:\/\/www.drugs.com\/price-guide\/skyclarys"},{"key":"2318_CR9","doi-asserted-by":"publisher","first-page":"118754","DOI":"10.1016\/j.jenvman.2023.118754","volume":"345","author":"T Fleischmann","year":"2023","unstructured":"Fleischmann T. Assessing the environmental fate of rAAV in activated sludge and water: implications for environmental risk assessments and GMO regulatory frameworks. J Environ Manage. 2023;345:118754.","journal-title":"J Environ Manage"},{"key":"2318_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000287207","volume":"62","author":"J Folker","year":"2010","unstructured":"Folker J, Murdoch B, Cahill L, Delatycki M, Corben L, Vogel A. Dysarthria in Friedreich\u2019s ataxia: a perceptual analysis. Folia Phoniatr Logop. 2010;62:97\u2013103.","journal-title":"Folia Phoniatr Logop"},{"key":"2318_CR11","unstructured":"Food and Drug Administration (FDA). 2022. Medical products for rare diseases and conditions. https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions"},{"issue":"2","key":"2318_CR12","first-page":"33","volume":"26","author":"BR Furrow","year":"2017","unstructured":"Furrow BR. The CRISPR-Cas9 tool of gene editing: cheaper, faster. Riskier? Annals Health L. 2017;26(2):33\u201351.","journal-title":"Riskier? Annals Health L"},{"key":"2318_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.24595","volume":"79","author":"CA Galea","year":"2016","unstructured":"Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, Gurrin LC, Lynch DR, Gelband S, Durr A, Pousset F, Parkinson M, Labrum R, Giunti P, Perlman SL, Delatycki MB, Evans-Galea MV. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016;79:485\u201395.","journal-title":"Ann Neurol"},{"issue":"3","key":"2318_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/15265161.2023.2180108","volume":"24","author":"I Galasso","year":"2024","unstructured":"Galasso I. Precision medicine for whom? Public health outputs from Genomics England and all of us to make up for upstream and downstream exclusion. Am J Bioeth. 2024;24(3):71\u201385.","journal-title":"Am J Bioeth"},{"key":"2318_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-030-42036-9_2","volume-title":"Human Enhancements for space missions: Lunar, Martian, and future missions to the outer planets","author":"AM Gouw","year":"2020","unstructured":"Gouw AM. CRISPR challenges and opportunities for space travel. In: Szocik K, editor. Human Enhancements for space missions: Lunar, Martian, and future missions to the outer planets. Switzerland: Springer Nature; 2020. pp. 19\u201334."},{"issue":"1","key":"2318_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4330\/wjc.v11.i1.1","volume":"11","author":"E Hanson","year":"2019","unstructured":"Hanson E, Sheldon M, Pacheco B, Alkubeysi M, Raizada V. Heart disease in Friedreich\u2019s ataxia. World J Cardiol. 2019;11(1):1\u201312.","journal-title":"World J Cardiol"},{"key":"2318_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jme.23.6.353","volume":"23","author":"J Harris","year":"1997","unstructured":"Harris J. Goodbye Dolly? The ethics of human cloning. J Med Ethics. 1997;23:353\u201360.","journal-title":"J Med Ethics"},{"key":"2318_CR18","doi-asserted-by":"crossref","unstructured":"Hohenfeld C, Terstiege U, Dogan I, Giunti P, Parkinson MH, Mariotti C, Nanetti L, Fichera M, Durr A, Ewenczyk C, Boesch S, Nachbauer W, Klopstock T, Stendel C, Rodr\u00edguez de Rivera Garrido, Sch\u00f6ls FJ, Hayer L, Klockgether SN, Giordano T, Didszun I, Rai C, Pandolfo M, Rauhut M, Schulz H, J. B., Reetz K. 2022. Prediction of the disease course in Friedreich ataxia. Nature Scientific Reports, 22, 19173.","DOI":"10.1038\/s41598-022-23666-z"},{"issue":"13","key":"2318_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1161\/CIRCULATIONAHA.112.095364","volume":"125","author":"MK Jensen","year":"2012","unstructured":"Jensen MK, Bundgaard H. Cardiomyopathy in Friedreich ataxia: exemplifying the challenges faced by cardiologists in the management of rare diseases. Circulation. 2012;125(13):1591\u20133.","journal-title":"Circulation"},{"key":"2318_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s00455-017-9804-4","volume":"32","author":"MJ Keage","year":"2017","unstructured":"Keage MJ, Delatycki MB, Gupta I, Corben LA, Vogel AP. Dysphagia Friedreich Ataxia Dysphagia. 2017;32:626\u201335.","journal-title":"Dysphagia Friedreich Ataxia Dysphagia"},{"key":"2318_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nbt.4207","volume":"36","author":"H Lee","year":"2018","unstructured":"Lee H, Kim J-S. Unexpected CRISPR on-target effects. Nat Biotechnol. 2018;36:703\u20134.","journal-title":"Nat Biotechnol"},{"key":"2318_CR22","unstructured":"Lexeo Therapeutics. 2024. Friedreich\u2019s ataxia: LX20006. Lexeotx.com. https:\/\/www.lexeotx.com\/programs\/cardiac-programs\/friedreichs-ataxia\/"},{"issue":"10","key":"2318_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.cardfail.2018.09.005","volume":"24","author":"CA Macrae","year":"2018","unstructured":"Macrae CA. Rare diseases inform myocardial phenotypes for precision medicine. J Card Fail. 2018;24(10):680\u20131.","journal-title":"J Card Fail"},{"key":"2318_CR24","unstructured":"Mayo Clinic. 2024. Gene therapy for cardiomyopathy associated with Friedreich\u2019s ataxia. Mayo Clinic Clinical Trials database. https:\/\/www.mayo.edu\/research\/clinical-trials\/cls-20542201"},{"key":"2318_CR25","unstructured":"Novartis. 2020. Novartis provides update on AVXS-101 Intrathecal Clinical Development Program. Novartis news, September 23, 2020. https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-avxs-101-intrathecal-clinical-development-program"},{"key":"2318_CR26","doi-asserted-by":"crossref","unstructured":"Ocana-Santero G, D\u00edaz-nido J, Herranz-Mart\u00edn S. 2021. Future Prospects of Gene Therapy for Friedreich\u2019s Ataxia. Int J Mol Sci, 22.","DOI":"10.3390\/ijms22041815"},{"issue":"2","key":"2318_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ajhg.2017.06.012","volume":"101","author":"KE Ormond","year":"2017","unstructured":"Ormond KE, Mortlock DP, Scholes DT, Bombard Y, Brody LC, Faucett WA, Garrison NA, Hercher L, Isasi R, Middleton A, Musunuru K, Shriner D, Virani A, Young CE. Human germline genome editing. Am J Hum Genet. 2017;101(2):167\u201376.","journal-title":"Am J Hum Genet"},{"key":"2318_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/B978-0-12-819178-1.00014-9","volume-title":"Precision Medicine for investigators, practitioners and providers","author":"F Palau","year":"2020","unstructured":"Palau F. Pediatric genomics and precision medicine in childhood. In: Faintuch J, Faintuch S, editors. Precision Medicine for investigators, practitioners and providers. Cambridge M. A.: Academic; 2020. pp. 143\u201352."},{"key":"2318_CR29","doi-asserted-by":"publisher","first-page":"120609","DOI":"10.1016\/j.jns.2023.120609","volume":"447","author":"E Papadopoulou","year":"2023","unstructured":"Papadopoulou E, Pepe G, Konitsiotis S, Chondrogiorgi M, Grigoriadis N, Kimiskidis VK, Tsivgoulis G, Mitsikostas DD, Chroni E, Domouzoglou E, Tsaousis G, Nasioulas G. The evolution of comprehensive genetic analysis in neurology: implications for precision medicine. J Neurol Sci. 2023;447:120609.","journal-title":"J Neurol Sci"},{"key":"2318_CR30","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s13311-020-00941-3","volume":"17","author":"SL Perlman","year":"2020","unstructured":"Perlman SL. Update on the treatment of ataxia: medication and emerging therapies. Neurotherapeutics. 2020;17:1660\u20134.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"2318_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/1746-5354-2-3-115","volume":"2","author":"A Plows","year":"2006","unstructured":"Plows A, Boddington P. Troubles with biocitizenship? Genomics Soc Policy. 2006;2(3):115\u201335.","journal-title":"Genomics Soc Policy"},{"key":"2318_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/13543784.2023.2173063","volume":"32","author":"V Profeta","year":"2023","unstructured":"Profeta V, McIntyre K, Wells M, Park C, Lynch DR. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia. Expert Opin Investig Drugs. 2023;32:5\u201316.","journal-title":"Expert Opin Investig Drugs"},{"key":"2318_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","volume":"14","author":"K Reetz","year":"2015","unstructured":"Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, Nanetti L, Arpa J, Sanz-Gallego I, Durr A, Charles P, Boesch S, Nachbauer W, Klopstock T, Karin I, Depondt C, Hagen V, Sch\u00f6ls JM, Giordano L, Klockgether IA, B\u00fcrk T, Pandolfo K, M., Schulz JB. Biological and clinical characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14:174\u201382.","journal-title":"Lancet Neurol"},{"key":"2318_CR34","unstructured":"Roberts R. 2021. Using CRISPR to defeat Friedreich\u2019s ataxia: A precision disease model and a novel cell therapy. CRISPR Medicine News, July 6, 2021. https:\/\/crisprmedicinenews.com\/news\/using-crispr-to-defeat-friedreichs-ataxia-a-precision-disease-model-and-a-novel-cell-therapy\/"},{"key":"2318_CR35","doi-asserted-by":"publisher","first-page":"903139","DOI":"10.3389\/fgeed.2022.903139","volume":"4","author":"A Sivakumar","year":"2022","unstructured":"Sivakumar A, Cherqui S. Advantages and limitations of Gene Therapy and Gene Editing for Friedreich\u2019s Ataxia. Front Genome Ed. 2022;4:903139.","journal-title":"Front Genome Ed"},{"key":"2318_CR36","doi-asserted-by":"crossref","unstructured":"Tiberi J, Segatto M, Fiorenza MT, La Rosa P. 2023. Apparent Opportunities and Hidden Pitfalls: The Conflicting Results of Restoring NRF2-Regulated Redox Metabolism in Friedreich\u2019s Ataxia Pre-Clinical Models and Clinical Trials. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051293"},{"key":"2318_CR37","doi-asserted-by":"publisher","first-page":"101179","DOI":"10.1016\/j.omtm.2023.101179","volume":"32","author":"SJ Trantham","year":"2024","unstructured":"Trantham SJ, Coker MA, Norman S, Crowley E, Berthy J, Byrne BJ, Subramony S, LOU X, Corti M. Perspectives of the Friedreich ataxia community on gene therapy clinical trials. Mol Therapy - Methods Clin Dev. 2024;32:101179.","journal-title":"Mol Therapy - Methods Clin Dev"},{"key":"2318_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.fct.2017.06.033","volume":"107","author":"AM Tsatsakis","year":"2017","unstructured":"Tsatsakis AM, Nawaz MA, Tutelyan VA, Golokhvast KS, Kalantzi O-I, Chung DH, Kang SJ, Coleman MD, Tyshko N, Yang SH, Chung G. Impact on environment, ecosystem, diversity and health from culturing and using GMOs as feed and food. Food Chem Toxicol. 2017;107:108\u201321.","journal-title":"Food Chem Toxicol"},{"key":"2318_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, Ravina B, Koeppen AH, Lynch DR. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307:46\u20139.","journal-title":"J Neurol Sci"},{"key":"2318_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2049-1891-4-37","volume":"4","author":"AL Van Eenennaam","year":"2013","unstructured":"Van Eenennaam AL. GMOs in animal agriculture: time to consider both costs and benefits in regulatory evaluations. J Anim Sci Biotechnol. 2013;4:37.","journal-title":"J Anim Sci Biotechnol"},{"issue":"3","key":"2318_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/15265161.2024.2303153","volume":"24","author":"JNM Via\u00f1a","year":"2024","unstructured":"Via\u00f1a JNM. All from us or all with us: addressing precision medicine inequities requires inclusion of intersectionally minoritized populations as partners and project leaders. Am J Bioeth. 2024;24(3):111\u20134.","journal-title":"Am J Bioeth"},{"issue":"3","key":"2318_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ajmg.1320340327","volume":"34","author":"J Wallis","year":"1989","unstructured":"Wallis J, Shaw J, Wilkes D, Farrall M, Williamson R, Chamberlain S, Skare JC, Milunsky A. Prenatal diagnosis of Friedreich ataxia. Am J Med Genet. 1989;34(3):458\u201361.","journal-title":"Am J Med Genet"},{"key":"2318_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jppr.1742","volume":"51","author":"TL Webb","year":"2021","unstructured":"Webb TL, Hong E. GMO Medicines and hospital pharmacy practice: a review. J Pharm Pract Res. 2021;51:203\u201310.","journal-title":"J Pharm Pract Res"},{"key":"2318_CR44","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.drudis.2021.11.003","volume":"27","author":"W Yang","year":"2022","unstructured":"Yang W, Thompson B, Kwa FAA. Molecular approaches for the treatment and prevention of Friedreich\u2019s ataxia. Drug Discov Today. 2022;27:866\u201380.","journal-title":"Drug Discov Today"}],"container-title":["International Journal for Equity in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-024-02318-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12939-024-02318-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-024-02318-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:03:23Z","timestamp":1731042203000},"score":1,"resource":{"primary":{"URL":"https:\/\/equityhealthj.biomedcentral.com\/articles\/10.1186\/s12939-024-02318-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1186\/s12939-024-02318-w","relation":{},"ISSN":["1475-9276"],"issn-type":[{"value":"1475-9276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"E Kendal is a special issue guest editor for IJfEiH. F Kwa conducts laboratory research in FA and liaises with stakeholders from the community, pharmaceutical companies, healthcare professionals, and other universities, as required. No funding has been received for this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"230"}}